Ad26. ZEBOV

BIOLOGICAL2 trials

Sponsors

Crucell Holland BV, Janssen Vaccines & Prevention B.V.

Conditions

Healthy

Phase 1

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

CompletedNCT02313077

Crucell Holland BVHealthy

Start: 2014-12-17End: 2016-03-15Updated: 2017-04-14

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

CompletedNCT02325050

Janssen Vaccines & Prevention B.V.Healthy

Start: 2015-01-08End: 2017-05-08Updated: 2017-06-14

Related Papers

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

2021-12-207 citations

Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol

BMJ Open2021-09-0125 citations

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

Journal of Clinical Investigation2020-04-2119 citations

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

The Journal of Infectious Diseases2019-02-19148 citations

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

JAMA2016-04-19321 citations